Loading clinical trials...
Loading clinical trials...
A Phase 1 Open Label, Multi-Center Study to Evaluate the Safety and Tolerability of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) and Diffuse Midline Glioma (DMG)
Conditions
Interventions
BXQ-350 - Part 1 Dose Escalation: Safety and Tolerance
BXQ-350 - Part 2 BXQ-350 Tumor and Plasma Concentrations
Locations
3
United States
Children's Hospital Colorado
Aurora, Colorado, United States
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
Nationwide Children's
Columbus, Ohio, United States
Start Date
May 24, 2021
Primary Completion Date
October 4, 2024
Completion Date
October 4, 2024
Last Updated
December 20, 2024
NCT05839379
NCT04943848
NCT04870944
NCT05762419
NCT05077735
NCT05259605
Lead Sponsor
Bexion Pharmaceuticals, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions